AABDF22D-9C2A-4994-A2D7-5167F23DDF36
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 30.091984231274637
- age_years
- 40
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.549
- G2M_CHECKPOINT+0.515
- MYC_TARGETS_V1+0.498
- WNT_BETA_CATENIN_SIGNALING+0.457
- MYC_TARGETS_V2+0.456
- DNA_REPAIR+0.408
- CHOLESTEROL_HOMEOSTASIS+0.401
- UNFOLDED_PROTEIN_RESPONSE+0.368
- OXIDATIVE_PHOSPHORYLATION+0.365
- MTORC1_SIGNALING+0.357
Top 10 suppressed
- KRAS_SIGNALING_DN-0.352
- MYOGENESIS-0.146
- SPERMATOGENESIS-0.126
- APICAL_SURFACE-0.117
- APICAL_JUNCTION-0.077
- COAGULATION-0.030
- ALLOGRAFT_REJECTION+0.005
- UV_RESPONSE_DN+0.036
- INFLAMMATORY_RESPONSE+0.039
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.039
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4FE5EDE2-7790-4A75-9BB6-93260A8154A0 | — | — | 0.927 |
| 2 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.900 |
| 3 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.894 |
| 4 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.892 |
| 5 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.888 |
| 6 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.887 |
| 7 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.885 |
| 8 | 5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4 | — | — | 0.884 |
| 9 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.884 |
| 10 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.549 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.515 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.498 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.457 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.456 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.408 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.401 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.368 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.365 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.357 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.343 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.311 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.296 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.285 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.273 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.266 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.259 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.255 | Idelalisib | — uncovered |
| APOPTOSIS | 0.246 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.241 | Inavolisib | — uncovered |